CL2017000367A1 - Proceso para preparar intermediarios sintéticos para preparar derivados de tetrahidroquinolina - Google Patents
Proceso para preparar intermediarios sintéticos para preparar derivados de tetrahidroquinolinaInfo
- Publication number
- CL2017000367A1 CL2017000367A1 CL2017000367A CL2017000367A CL2017000367A1 CL 2017000367 A1 CL2017000367 A1 CL 2017000367A1 CL 2017000367 A CL2017000367 A CL 2017000367A CL 2017000367 A CL2017000367 A CL 2017000367A CL 2017000367 A1 CL2017000367 A1 CL 2017000367A1
- Authority
- CL
- Chile
- Prior art keywords
- prepare
- synthetic intermediates
- tetrahydroquinoline derivatives
- preparing synthetic
- derivatives
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003530 tetrahydroquinolines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2014050556 | 2014-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000367A1 true CL2017000367A1 (es) | 2018-02-09 |
Family
ID=51429345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000367A CL2017000367A1 (es) | 2014-08-12 | 2017-02-10 | Proceso para preparar intermediarios sintéticos para preparar derivados de tetrahidroquinolina |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10112904B2 (OSRAM) |
| EP (2) | EP3180314B1 (OSRAM) |
| JP (1) | JP6670310B2 (OSRAM) |
| KR (1) | KR102572626B1 (OSRAM) |
| CN (1) | CN107108558B (OSRAM) |
| AR (1) | AR101509A1 (OSRAM) |
| AU (1) | AU2015302407B2 (OSRAM) |
| BR (1) | BR112017002873B1 (OSRAM) |
| CA (1) | CA2958040C (OSRAM) |
| CL (1) | CL2017000367A1 (OSRAM) |
| DK (1) | DK3180314T3 (OSRAM) |
| EA (1) | EA034357B1 (OSRAM) |
| ES (1) | ES2926775T3 (OSRAM) |
| HR (1) | HRP20221061T1 (OSRAM) |
| HU (1) | HUE059947T2 (OSRAM) |
| IL (1) | IL250525B (OSRAM) |
| LT (1) | LT3180314T (OSRAM) |
| MA (1) | MA40378B1 (OSRAM) |
| MX (1) | MX367908B (OSRAM) |
| PL (1) | PL3180314T3 (OSRAM) |
| PT (1) | PT3180314T (OSRAM) |
| RS (1) | RS63575B1 (OSRAM) |
| SG (1) | SG11201701077XA (OSRAM) |
| SI (1) | SI3180314T1 (OSRAM) |
| SM (1) | SMT202200385T1 (OSRAM) |
| TW (1) | TWI691490B (OSRAM) |
| WO (1) | WO2016024858A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE067276T2 (hu) | 2021-03-05 | 2024-10-28 | Newamsterdam Pharma B V | Obicetrapib demenciák kezelésére |
| CA3227153A1 (en) | 2021-07-26 | 2023-02-02 | Newamsterdam Pharma B.V. | Treatment of his hyporesponders |
| EP4456872A1 (en) | 2021-12-30 | 2024-11-06 | NewAmsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
| AR129814A1 (es) | 2022-07-05 | 2024-10-02 | Newamsterdam Pharma B V | Sales de obicetrapib y procesos para su fabricación y productos intermedios de estos |
| WO2024042061A1 (en) | 2022-08-22 | 2024-02-29 | Newamsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
| WO2024165395A1 (en) | 2023-02-07 | 2024-08-15 | Newamsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
| WO2025059594A1 (en) | 2023-09-15 | 2025-03-20 | Newamsterdam Pharma B.V. | METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH) |
| WO2025093436A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025093129A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025146262A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Obicetrapib for use in the treatment of hemoglobinopathies |
| WO2025146415A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Improvement in atherosclerotic plaque characteristics with obicetrapib |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| PL366700A1 (en) * | 2001-04-30 | 2005-02-07 | Pfizer Products Inc. | Methods for preparing cetp inhibitors |
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| TW200808731A (en) * | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
| CN101466679A (zh) * | 2006-03-30 | 2009-06-24 | 田边三菱制药株式会社 | 制备四氢喹啉衍生物的方法 |
-
2015
- 2015-07-29 EP EP15767345.0A patent/EP3180314B1/en active Active
- 2015-07-29 CA CA2958040A patent/CA2958040C/en active Active
- 2015-07-29 CN CN201580046606.1A patent/CN107108558B/zh active Active
- 2015-07-29 PL PL15767345.0T patent/PL3180314T3/pl unknown
- 2015-07-29 WO PCT/NL2015/050555 patent/WO2016024858A1/en not_active Ceased
- 2015-07-29 ES ES15767345T patent/ES2926775T3/es active Active
- 2015-07-29 DK DK15767345.0T patent/DK3180314T3/da active
- 2015-07-29 EP EP22179712.9A patent/EP4083022A1/en active Pending
- 2015-07-29 JP JP2017528754A patent/JP6670310B2/ja active Active
- 2015-07-29 MA MA40378A patent/MA40378B1/fr unknown
- 2015-07-29 RS RS20220810A patent/RS63575B1/sr unknown
- 2015-07-29 EA EA201790364A patent/EA034357B1/ru active IP Right Revival
- 2015-07-29 HR HRP20221061TT patent/HRP20221061T1/hr unknown
- 2015-07-29 MX MX2017001930A patent/MX367908B/es active IP Right Grant
- 2015-07-29 BR BR112017002873-5A patent/BR112017002873B1/pt active IP Right Grant
- 2015-07-29 US US15/503,686 patent/US10112904B2/en active Active
- 2015-07-29 HU HUE15767345A patent/HUE059947T2/hu unknown
- 2015-07-29 SG SG11201701077XA patent/SG11201701077XA/en unknown
- 2015-07-29 SM SM20220385T patent/SMT202200385T1/it unknown
- 2015-07-29 SI SI201531874T patent/SI3180314T1/sl unknown
- 2015-07-29 PT PT157673450T patent/PT3180314T/pt unknown
- 2015-07-29 AU AU2015302407A patent/AU2015302407B2/en active Active
- 2015-07-29 KR KR1020177006422A patent/KR102572626B1/ko active Active
- 2015-07-29 LT LTEPPCT/NL2015/050555T patent/LT3180314T/lt unknown
- 2015-08-10 TW TW104125888A patent/TWI691490B/zh active
- 2015-08-11 AR ARP150102597A patent/AR101509A1/es active IP Right Grant
-
2017
- 2017-02-09 IL IL250525A patent/IL250525B/en active IP Right Grant
- 2017-02-10 CL CL2017000367A patent/CL2017000367A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000367A1 (es) | Proceso para preparar intermediarios sintéticos para preparar derivados de tetrahidroquinolina | |
| SG10201806846RA (en) | Cyclopropylamines as lsd1 inhibitors | |
| PH12016501601A1 (en) | Cyclopropylamines as lsd1 inhibitors | |
| SG11201610028TA (en) | Compositions and methods of delivering treatments for latent viral infections | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| TW201613860A (en) | Cyclopropylamines as LSD1 inhibitors | |
| EP3186278A4 (en) | Internalizing moieties for treatment of cancer | |
| EP3151818A4 (en) | Compositions and methods of treating diabetic retinopathy | |
| PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
| EP3122782A4 (en) | Compositions and methods for treatment of diabetic macular edema | |
| BR112016025792A2 (pt) | meios e processos para tratamento de cmv | |
| CL2017001135A1 (es) | Anticuerpos mejorados contra il-6 | |
| SG11201607996SA (en) | Effect of lipophilic nutrients on diabetic eye diseases | |
| SI3116519T1 (sl) | Topični sestavki, ki obsegajo izvleček coriolusa versicolora za izboljšanje avtoimunosti | |
| PT3233071T (pt) | Método de tratamento ou prevenção de doenças mediadas por ras | |
| EP3204352A4 (en) | Inhibitors of lysine gingipain | |
| ZA201703467B (en) | Methods of treating ocular conditions | |
| EP3322406A4 (en) | TRANSPAPILLARY METHOD AND COMPOSITION FOR THE TREATMENT OF BREAST DISEASES | |
| PT3142641T (pt) | Formulações para o tratamento de hipertiroidismo | |
| EP3393462A4 (en) | COMPOSITIONS AND METHODS FOR TREATING, REDUCING AND PREVENTING NARCOSE-INDUCED HYPOTHERMIA | |
| EP3156054A4 (en) | Medicine for preventing and/or treating stress-induced diseases | |
| EP3145532A4 (en) | Individualized treatment of eye disease | |
| EP3122867A4 (en) | Preparation of small colony variants of therapeutic bacteria | |
| ZA201608607B (en) | Novel fluoroquinolones and use thereof to treat bacterial infections | |
| EP3148563A4 (en) | Methods and compositions for enhancement of ability to concentrate |